Antidepressant Warnings On Pediatric Suicide Need Immediate Strengthening, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A joint FDA advisory committee says suicide risk warnings should be communicated to physicians and consumers while the agency re-analyzes pediatric data from antidepressant manufacturers.
You may also be interested in...
Antidepressant Suicidality Class Risk Will Be Reviewed By Advisory Committees
FDA releases analysis of pediatric suicidality data for joint meeting of Psychopharmacologic Drugs and Pediatric Advisory Committees. The analysis could result in label changes for antidepressants, FDA Talk Paper says.
Antidepressant Suicidality Class Risk Will Be Reviewed By Advisory Committees
FDA releases analysis of pediatric suicidality data for joint meeting of Psychopharmacologic Drugs and Pediatric Advisory Committees. The analysis could result in label changes for antidepressants, FDA Talk Paper says.
FDA Analysis Of Antidepressant Pediatric Suicidality Data To Be Reviewed Sept. 13-14
Joint meeting of Psychopharmacologic and newly formed Pediatric Advisory Committees will review analysis performed by expert group assembled by Columbia University. Future research needs in pediatric suicidality will also be addressed.